Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV-infection: A prospective case-control study

被引:104
作者
Cauda, R
Tacconelli, E
Tumbarello, M
Morace, G
De Bernardis, F
Torosantucci, A
Cassone, A
机构
[1] Univ Cattolica Sacro Cuore, Ist Clin Malattie Infett, Dept Infect Dis, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Microbiol, Rome, Italy
[3] Ist Super Sanita, Dept Bacteriol & Med Micol, I-00161 Rome, Italy
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 1999年 / 21卷 / 01期
关键词
HIV protease inhibitors; HAART; candidosis; Candida; HIV; AIDS;
D O I
10.1097/00126334-199905010-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study was conducted to evaluate the efficacy of highly active antiretroviral therapy (HAART) in preventing recurrence of oral candidosis (OC) associated with HIV. A prospective case-controlled observational study was performed in an inner-city university-hospital HIV/AIDS clinic. Ninety-three HIV-positive study subjects with a history of recurrent OC were divided into two groups: protease inhibitors (PI)-treated patients (group 1, n = 30) and non-PI-treated patients (group 2, n = 63). Study subjects were matched for sex, age, stage of HIV infection, and peripheral CD4(+) T-cell counts. The non-PI-treated group was further subdivided into the following three subgroups: HIV-positive study subjects treated with reverse transcriptase inhibitors (RTI; groups 2a and 2c) and HIV-positive study subjects not treated with RTIs (group 2b). Group 2c met the same inclusion criteria as group 2a had but was matched 6 months after the beginning of the study. We also assessed in vitro peripheral blood mononuclear cells (PBMC) and their lymphoproliferative response, as well as cutaneous delayed-type hypersensitivity (DTH) response to Candida-associated antigens in a randomly selected sample of study subjects divided into those treated with PIs and those who were not. During a 1-year follow-up, OC was diagnosed in 2 (7%) PI-treated and 23 (36%) non-PI-treated patients (p <.001). In addition to comparing findings in group 1 with those in group 2c, OC was detected in 14 (50%) non-PI-treated patients compared with no HAART-treated study subjects (p <.001). Only 41% of PI-treated study subjects had positive lymphoproliferative response in PBMCs and none was positive in terms of DTH to Candida antigens (p = not significant versus non-PI-treated study subjects). While objectively demonstrating a beneficial effect of HAART in preventing recurrence of OC infections, our findings suggest this effect cannot be not fully accounted for by reconstitution of anti-Candida cell-mediated immunity, given that other mechanisms, even of a nonimmune nature, could have some effect.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 17 条
[1]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[2]   Long-term evaluation of cellular immunity during antiretroviral therapy and immunization with human immunodeficiency virus type 1 (HIV-1) Env glycoprotein in HIV-1-infected persons [J].
Carlesimo, M ;
Pontesilli, O ;
Guerra, EC ;
Varani, AR ;
Bernardi, ML ;
Ricci, G ;
Alario, C ;
Pirillo, MF ;
Mattiacci, G ;
Leone, P ;
Cassone, A ;
Aiuti, F .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04) :904-912
[3]   Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy [J].
Carr, A ;
Marriott, D ;
Field, A ;
Vasak, E ;
Cooper, DA .
LANCET, 1998, 351 (9098) :256-261
[4]  
CASSONE A, 1998, 12 INT C AIDS GEN JU
[5]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[6]   Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis [J].
De Bernardis, F ;
Arancia, S ;
Morelli, L ;
Hube, B ;
Sanglard, D ;
Schäfer, W ;
Cassone, A .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :201-208
[7]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[8]   Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of Anti-Candida cell-mediated immune responses in humans [J].
Gomez, MJ ;
Torosantucci, A ;
Arancia, S ;
Maras, B ;
Parisi, L ;
Cassone, A .
INFECTION AND IMMUNITY, 1996, 64 (07) :2577-2584
[9]   Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir [J].
Kelleher, AD ;
Carr, A ;
Zaunders, J ;
Cooper, DA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) :321-329
[10]   ORAL CANDIDIASIS IN HIGH-RISK PATIENTS AS THE INITIAL MANIFESTATION OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
KLEIN, RS ;
HARRIS, CA ;
SMALL, CB ;
MOLL, B ;
LESSER, M ;
FRIEDLAND, GH .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (06) :354-358